Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) – Analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a report issued on Monday, May 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.84) per share for the quarter, down from their prior forecast of ($0.82). HC Wainwright has a “Buy” rating and a $100.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($3.04) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($2.96) EPS, Q1 2027 earnings at ($0.41) EPS and Q2 2027 earnings at ($0.04) EPS.
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.03. Rhythm Pharmaceuticals had a negative return on equity of 203.25% and a negative net margin of 93.33%.The firm had revenue of $60.11 million during the quarter, compared to the consensus estimate of $55.78 million. During the same period in the prior year, the company earned ($0.81) EPS. The company’s quarterly revenue was up 83.8% compared to the same quarter last year.
Get Our Latest Analysis on RYTM
Rhythm Pharmaceuticals Stock Performance
Shares of RYTM opened at $91.31 on Wednesday. The stock has a market capitalization of $6.26 billion, a PE ratio of -29.17 and a beta of 1.94. The company’s fifty day moving average is $87.59 and its 200 day moving average is $98.84. Rhythm Pharmaceuticals has a fifty-two week low of $55.31 and a fifty-two week high of $122.20.
Insider Buying and Selling
In other Rhythm Pharmaceuticals news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at $11,190,445.12. This represents a 3.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Christopher Paul German sold 5,614 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total value of $502,789.84. Following the completion of the sale, the chief accounting officer owned 160 shares in the company, valued at approximately $14,329.60. The trade was a 97.23% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 15,160 shares of company stock worth $1,465,022. Insiders own 5.90% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Rhythm Pharmaceuticals by 39.2% in the 3rd quarter. Vanguard Group Inc. now owns 4,996,427 shares of the company’s stock valued at $504,589,000 after buying an additional 1,407,313 shares during the period. RA Capital Management L.P. increased its position in shares of Rhythm Pharmaceuticals by 17.3% during the fourth quarter. RA Capital Management L.P. now owns 6,666,837 shares of the company’s stock worth $713,618,000 after acquiring an additional 985,478 shares during the period. Alliancebernstein L.P. raised its stake in shares of Rhythm Pharmaceuticals by 1,493.8% during the third quarter. Alliancebernstein L.P. now owns 979,682 shares of the company’s stock valued at $98,938,000 after acquiring an additional 918,212 shares in the last quarter. Capital Research Global Investors bought a new stake in shares of Rhythm Pharmaceuticals during the third quarter valued at approximately $60,417,000. Finally, Jennison Associates LLC boosted its holdings in shares of Rhythm Pharmaceuticals by 123.2% in the fourth quarter. Jennison Associates LLC now owns 918,567 shares of the company’s stock valued at $98,323,000 after purchasing an additional 507,017 shares during the period.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.
The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
Featured Stories
- Five stocks we like better than Rhythm Pharmaceuticals
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
